Corporate Actions

Evonile Pharma plans to raise up to Rs 9,000 million through a rights issue

08-Oct-26   20:13 Hrs IST

Evonile Pharma Limited (formerly Novartis India Limited) plans to raise up to Rs 9,000 million through a rights issue of partly paid-up equity shares with a face value of Rs 5 each, to be offered to eligible shareholders on a record date to be determined later, subject to statutory and regulatory approvals. The company has constituted a Rights Issue Committee to finalize the issue details, including the rights entitlement ratio and issue price, and the total number of securities to be issued will be determined at a later date. The board also approved a postal ballot notice for shareholder approval and the launch of a new corporate website at www.evonilepharma.com.

Attention Investors:

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. || KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. || No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.